{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T10:45:53Z","timestamp":1785321953776,"version":"3.55.0"},"reference-count":42,"publisher":"The Endocrine Society","issue":"4","license":[{"start":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T00:00:00Z","timestamp":1609372800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2017YFC1309004"],"award-info":[{"award-number":["2017YFC1309004"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005150","name":"Chinese Academy of Medical Sciences","doi-asserted-by":"publisher","award":["2017-I2M-1\u2013005"],"award-info":[{"award-number":["2017-I2M-1\u2013005"]}],"id":[{"id":"10.13039\/501100005150","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,3,25]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>A standardized procedure of fused REarranged during Transfection (RET) gene detection using fluorescence in situ hybridization (FISH) remains to be established in papillary thyroid carcinoma (PTC). Our purpose was to investigate false-negative and false-positive events and their FISH signal characteristics.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>A total of 111 PTC cases were analyzed using break-apart FISH probes for RET status evaluation. All FISH results were validated using fusion-induced asymmetric transcription assay (FIATA)-based reverse transcription droplet digital PCR (RT-ddPCR). Then, suspected RET-positive cases were tested using quantitative reverse transcription-PCR (RT-qPCR), followed by next-generation sequencing (NGS) for recognizing fusion variants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Thirty RET+ cases were revealed, including 20 CCDC6 (exon 1)-RET (exon 12), 6 NCOA4 (exon 8)-RET (exon 12), 1 NCOA4 (exon 7)-RET (exon 12), 1 CCDC186 (exon 7)-RET (exon 12), 1 ERC1 (exon 12)-RET (exon 12) and 1 SPECC1L (exon 9)-RET (exon 12) tumors. All RET fusion cases occurred in the BRAF- population, with a prevalence of 41.7% (30\/72). Four cases of 8% to 13% (cutoff was 7.6%) dominant isolated 3\u2032 green (IG) FISH signals were RET-. One FISH- case with isolated 5\u2032 red (IR) signals with 94% abnormal tumor cells was demonstrated to be positive, harboring the NCOA4 (exon 7)-RET (exon 12) variant. Compared with RET fusions characterized by dominant break-apart signals with 29% to 100% aberrant cells, RET + with dominant IG-signal patterns all showed more frequent FISH+ cells (84%-92%). RET+ PTC with a break-apart signal pattern was more frequently found in unifocal lesions than in multifocal\/bilateral tumors (P = 0.049).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>A false-positive or false-negative event may exist for RET status detection in PTCs using the traditional FISH scoring method with break-apart probes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1210\/clinem\/dgaa913","type":"journal-article","created":{"date-parts":[[2020,12,31]],"date-time":"2020-12-31T14:30:10Z","timestamp":1609425010000},"page":"e1129-e1138","source":"Crossref","is-referenced-by-count":19,"title":["Pitfalls in <i>RET<\/i> Fusion Detection Using Break-Apart FISH Probes in Papillary Thyroid Carcinoma"],"prefix":"10.1210","volume":"106","author":[{"given":"Yuanyuan","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Molecular Pathology Research Center, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shafei","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Molecular Pathology Research Center, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liangrui","family":"Zhou","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Molecular Pathology Research Center, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8711-753X","authenticated-orcid":false,"given":"Xuan","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Pathology, Peking Union Medical College Hospital, Molecular Pathology Research Center, Chinese Academy of Medical Sciences, Beijing, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2020,12,31]]},"reference":[{"key":"2021122205131742200_CIT0001","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1038\/modpathol.2010.129","article-title":"Papillary thyroid carcinoma: an update","volume":"24(","author":"LiVolsi","year":"2011","journal-title":"Mod Pathol."},{"issue":"2","key":"2021122205131742200_CIT0002","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1210\/en.2005-0280","article-title":"BRAF mediates RET\/PTC-induced mitogen-activated protein kinase activation in thyroid cells: functional support for requirement of the RET\/PTC-RAS-BRAF pathway in papillary thyroid carcinogenesis","volume":"147","author":"Mitsutake","year":"2006","journal-title":"Endocrinology."},{"issue":"3","key":"2021122205131742200_CIT0003","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/j.cell.2014.09.050","article-title":"Integrated genomic characterization of papillary thyroid carcinoma","volume":"159","author":"Cancer Genome Atlas Research Network","year":"2014","journal-title":"Cell."},{"issue":"2","key":"2021122205131742200_CIT0004","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1002\/path.5005","article-title":"Genetic landscape of papillary thyroid carcinoma in the Chinese population","volume":"244","author":"Liang","year":"2018","journal-title":"J Pathol."},{"issue":"4","key":"2021122205131742200_CIT0005","doi-asserted-by":"crossref","first-page":"R117","DOI":"10.1530\/EJE-15-0605","article-title":"ENDOCRINE TUMOURS: Genetic predictors of thyroid cancer outcome","volume":"174","author":"Tavares","year":"2016","journal-title":"Eur J Endocrinol."},{"issue":"5","key":"2021122205131742200_CIT0006","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1530\/eje.1.02289","article-title":"RET\/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize Lecture","volume":"155","author":"Santoro","year":"2006","journal-title":"Eur J Endocrinol."},{"key":"2021122205131742200_CIT0007","doi-asserted-by":"crossref","first-page":"54","DOI":"10.3389\/fendo.2012.00054","article-title":"RET\/PTC translocations and clinico-pathological features in human papillary thyroid carcinoma","volume":"3","author":"Romei","year":"2012","journal-title":"Front Endocrinol (Lausanne)."},{"issue":"2","key":"2021122205131742200_CIT0008","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1089\/thy.2017.0318","article-title":"gene fusions in thyroid cancer","volume":"28","author":"Yakushina","year":"2018","journal-title":"Thyroid."},{"issue":"13","key":"2021122205131742200_CIT0009","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1002\/cncr.29044","article-title":"The RET oncogene in papillary thyroid carcinoma","volume":"121","author":"Prescott","year":"2015","journal-title":"Cancer."},{"key":"2021122205131742200_CIT0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.phrs.2017.12.021","article-title":"Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers","volume":"128","author":"Roskoski","year":"2018","journal-title":"Pharmacol Res."},{"issue":"15","key":"2021122205131742200_CIT0011","doi-asserted-by":"crossref","first-page":"4908","DOI":"10.1158\/1078-0432.CCR-07-1772","article-title":"Sorafenib potently inhibits papillary thyroid carcinomas harboring RET\/PTC1 rearrangement","volume":"14","author":"Henderson","year":"2008","journal-title":"Clin Cancer Res."},{"issue":"5","key":"2021122205131742200_CIT0012","doi-asserted-by":"crossref","first-page":"458","DOI":"10.4161\/cbt.12.5.16303","article-title":"Sunitinib inhibits papillary thyroid carcinoma with RET\/PTC rearrangement but not BRAF mutation","volume":"12","author":"Jeong","year":"2011","journal-title":"Cancer Biol Ther."},{"issue":"11","key":"2021122205131742200_CIT0013","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1200\/JCO.19.02551","article-title":"State-of-the-art strategies for targeting RET-dependent cancers","volume":"38","author":"Subbiah","year":"2020","journal-title":"J Clin Oncol."},{"issue":"12","key":"2021122205131742200_CIT0014","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1038\/labinvest.3700198","article-title":"Real-time quantitative RT-PCR identifies distinct c-RET, RET\/PTC1 and RET\/PTC3 expression patterns in papillary thyroid carcinoma","volume":"84","author":"Rhoden","year":"2004","journal-title":"Lab Invest."},{"issue":"1","key":"2021122205131742200_CIT0015","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S0039-6060(99)70287-4","article-title":"Oncogene profile of papillary thyroid carcinoma","volume":"125","author":"Sugg","year":"1999","journal-title":"Surgery."},{"issue":"10","key":"2021122205131742200_CIT0016","first-page":"3631","article-title":"RET\/PTC and RET tyrosine kinase expression in adult papillary thyroid carcinomas","volume":"83","author":"Learoyd","year":"1998","journal-title":"J Clin Endocrinol Metab."},{"issue":"6","key":"2021122205131742200_CIT0017","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1210\/jc.2006-0240","article-title":"RET\/papillary thyroid cancer rearrangement in nonneoplastic thyrocytes: follicular cells of Hashimoto\u2019s thyroiditis share low-level recombination events with a subset of papillary carcinoma","volume":"91","author":"Rhoden","year":"2006","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205131742200_CIT0018","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1507\/endocrj.K10E-260","article-title":"Prevalence of RET\/PTC rearrangement in benign and malignant thyroid nodules and its clinical application","volume":"58","author":"Guerra","year":"2011","journal-title":"Endocr J."},{"issue":"6","key":"2021122205131742200_CIT0019","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/j.ejso.2018.11.009","article-title":"Detection of RET rearrangements in papillary thyroid carcinoma using RT-PCR and FISH techniques - a molecular and clinical analysis","volume":"45","author":"Musholt","year":"2019","journal-title":"Eur J Surg Oncol."},{"issue":"1","key":"2021122205131742200_CIT0020","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1002\/(SICI)1096-9896(199805)185:1<71::AID-PATH42>3.0.CO;2-S","article-title":"Sporadic ret-rearranged papillary carcinoma of the thyroid: a subset of slow growing, less aggressive thyroid neoplasms?","volume":"185","author":"Soares","year":"1998","journal-title":"J Pathol."},{"issue":"2","key":"2021122205131742200_CIT0021","first-page":"287","article-title":"RET\/PTC oncogene activation defines a subset of papillary thyroid carcinomas lacking evidence of progression to poorly differentiated or undifferentiated tumor phenotypes","volume":"4","author":"Tallini","year":"1998","journal-title":"Clin Cancer Res."},{"issue":"3","key":"2021122205131742200_CIT0022","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1002\/gcc.22229","article-title":"An evaluation and recommendation of the optimal methodologies to detect RET gene rearrangements in papillary thyroid carcinoma","volume":"54","author":"Zhang","year":"2015","journal-title":"Genes Chromosomes Cancer."},{"issue":"11","key":"2021122205131742200_CIT0023","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1089\/thy.2015.0305","article-title":"Impact of the multi-gene ThyroSeq next-generation sequencing assay on cancer diagnosis in thyroid nodules with atypia of undetermined significance\/follicular lesion of undetermined significance cytology","volume":"25","author":"Nikiforov","year":"2015","journal-title":"Thyroid."},{"issue":"8","key":"2021122205131742200_CIT0024","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1158\/1078-0432.CCR-16-1679","article-title":"RET aberrations in diverse cancers: next-generation sequencing of 4,871 patients","volume":"23","author":"Kato","year":"2017","journal-title":"Clin Cancer Res."},{"issue":"4","key":"2021122205131742200_CIT0025","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1530\/ERC-13-0157","article-title":"Assessing RET\/PTC in thyroid nodule fine-needle aspirates: the FISH point of view","volume":"20","author":"Caria","year":"2013","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"2021122205131742200_CIT0026","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1530\/EJE-14-0930","article-title":"Break-apart interphase fluorescence in situ hybridization assay in papillary thyroid carcinoma: on the road to optimizing the cut-off level for RET\/PTC rearrangements","volume":"172","author":"Colato","year":"2015","journal-title":"Eur J Endocrinol."},{"issue":"2","key":"2021122205131742200_CIT0027","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s12022-009-9101-3","article-title":"Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET\/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas","volume":"21","author":"Sadow","year":"2010","journal-title":"Endocr Pathol."},{"issue":"12","key":"2021122205131742200_CIT0028","doi-asserted-by":"crossref","first-page":"5577","DOI":"10.1002\/cam4.2478","article-title":"BRAFV600E mutation analysis in fine-needle aspiration cytology specimens for diagnosis of thyroid nodules: The influence of false-positive and false-negative results","volume":"8","author":"Zhao","year":"2019","journal-title":"Cancer Med."},{"issue":"8","key":"2021122205131742200_CIT0029","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1111\/1759-7714.13535","article-title":"Clinical evaluation of the effectiveness of fusion-induced asymmetric transcription assay-based reverse transcription droplet digital PCR for ALK detection in formalin-fixed paraffin-embedded samples from lung cancer","volume":"11","author":"Liu","year":"2020","journal-title":"Thorac Cancer."},{"issue":"2","key":"2021122205131742200_CIT0030","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jmoldx.2017.11.004","article-title":"Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine Kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology","volume":"20","author":"Lindeman","year":"2018","journal-title":"J Mol Diagn."},{"key":"2021122205131742200_CIT0031","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.humpath.2020.01.003","article-title":"The updated 2018 American Society of Clinical Oncology\/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups","volume":"98","author":"Woo","year":"2020","journal-title":"Hum Pathol."},{"issue":"3","key":"2021122205131742200_CIT0032","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/nrclinonc.2017.175","article-title":"Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes","volume":"15","author":"Drilon","year":"2018","journal-title":"Nat Rev Clin Oncol."},{"issue":"9","key":"2021122205131742200_CIT0033","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1210\/jc.2003-031870","article-title":"Heterogeneity in the distribution of RET\/PTC rearrangements within individual post-Chernobyl papillary thyroid carcinomas","volume":"89","author":"Unger","year":"2004","journal-title":"J Clin Endocrinol Metab."},{"issue":"1","key":"2021122205131742200_CIT0034","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.breast.2011.07.009","article-title":"Comparative study of spatial localization of HER-2 and CEP17 signals and of HER-2\/CEP17 ratios, in \u201cthin\u201d and \u201cthick\u201d tissue sections","volume":"21","author":"Kouvaras","year":"2012","journal-title":"Breast."},{"issue":"5","key":"2021122205131742200_CIT0035","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.3892\/or.2014.3402","article-title":"Fluorescence in situ hybridization of chromosome 17 polysomy in breast cancer using thin tissue sections causes the loss of CEP17 and HER2 signals","volume":"32","author":"Jiang","year":"2014","journal-title":"Oncol Rep."},{"issue":"4","key":"2021122205131742200_CIT0036","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1038\/s41374-017-0007-2","article-title":"Use of multicolor fluorescence in situ hybridization to detect deletions in clinical tissue sections","volume":"98","author":"Yoshimoto","year":"2018","journal-title":"Lab Invest."},{"issue":"12","key":"2021122205131742200_CIT0037","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1038\/labinvest.3780377","article-title":"Frequent RET rearrangements in thyroid papillary microcarcinoma detected by interphase fluorescence in situ hybridization","volume":"81","author":"Corvi","year":"2001","journal-title":"Lab Invest."},{"issue":"5","key":"2021122205131742200_CIT0038","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1089\/thy.2016.0254","article-title":"Molecular pathology of anaplastic thyroid carcinomas: a retrospective study of 144 cases","volume":"27","author":"Bonhomme","year":"2017","journal-title":"Thyroid."},{"issue":"1","key":"2021122205131742200_CIT0039","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s00428-009-0789-8","article-title":"RET\/PTC rearrangements arising from a small population of papillary thyroid carcinoma cells, possible candidate for passenger mutation","volume":"455","author":"Nakazawa","year":"2009","journal-title":"Virchows Arch."},{"issue":"7","key":"2021122205131742200_CIT0040","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1002\/cyto.a.20557","article-title":"Automated FISH analysis using dual-fusion and break-apart probes on paraffin-embedded tissue sections","volume":"73","author":"Alp\u00e1r","year":"2008","journal-title":"Cytometry A."},{"issue":"5","key":"2021122205131742200_CIT0041","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1007\/s00432-020-03166-1","article-title":"ALK detection in lung cancer: identification of atypical and cryptic ALK rearrangements using an optimal algorithm","volume":"146","author":"Liu","year":"2020","journal-title":"J Cancer Res Clin Oncol."},{"issue":"4","key":"2021122205131742200_CIT0042","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1677\/JME-08-0063","article-title":"Molecular analysis of multifocal papillary thyroid carcinoma","volume":"41","author":"Lin","year":"2008","journal-title":"J Mol Endocrinol."}],"container-title":["The Journal of Clinical Endocrinology &amp; Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jcem\/advance-article-pdf\/doi\/10.1210\/clinem\/dgaa913\/35331830\/dgaa913.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/4\/e1129\/41848057\/dgaa913.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jcem\/article-pdf\/106\/4\/e1129\/41848057\/dgaa913.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,22]],"date-time":"2021-12-22T05:19:59Z","timestamp":1640150399000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jcem\/article\/106\/4\/e1129\/6056485"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12,31]]},"references-count":42,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2020,12,31]]},"published-print":{"date-parts":[[2021,3,25]]}},"URL":"https:\/\/doi.org\/10.1210\/clinem\/dgaa913","relation":{},"ISSN":["0021-972X","1945-7197"],"issn-type":[{"value":"0021-972X","type":"print"},{"value":"1945-7197","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,4,1]]},"published":{"date-parts":[[2020,12,31]]}}}